Fondaparinux is associated with substantially less major bleeding and vascular access site complications compared with enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the OASIS 5 trial Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Mehta, Shamir
  • Bassand, JP
  • Granger, CB
  • Widimsky, P
  • Steg, PG
  • Rupprecht, HJ
  • Faxon, DP
  • Afzal, R
  • Chrolavicius, S
  • Meeks, B
  • Fox, KAA
  • Yusuf, Salim

publication date

  • February 21, 2006